Timing of Postoperative Radiotherapy for High-Risk Prostate Cancer

Event-free survival was not improved with immediate adjuvant radiotherapy versus early salvage radiotherapy after prostatectomy.

The RADICALS-RT study (NEJM JW Oncol Hematol Nov 2020 and Lancet 2020 Sep 28; [e-pub]) showed that prostate-specific antigen (PSA) progression–free survival was not improved with immediate adjuvant versus early salvage radiotherapy after prostatectomy in men with high-risk prostate cancer.

To further compare adjuvant radiotherapy (RT) with early salvage RT in this setting, an international group of investigators conducted an adaptive meta-analysis (begun while eligible trials were ongoing) involving 2153 patients from three randomized, phase III studies: 1396 patients from the RADICALS-RT trial, 424 from the GETUG-AFU 17 trial (Lancet Oncol 2020; 21:1341), and 333 from the TROG 08.03/ANZUP RAVES trial (Lancet Oncol 2020; 21:1331); the primar…

Reviewing Author

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Timing of Postoperative Radiotherapy for High-Risk Prostate Cancer

Topics

Reviewing Author